- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04526561
Reconstructions With Back Donor Site Flaps and Validation of Quality of Life Scales
August 7, 2023 updated by: Vastra Gotaland Region
The latissimus dorsi flap is the oldest and most used technique for breast reconstruction. Nonetheless, there are few studies evaluation the long-term effect of harvesting one of the muscles of the back. This project has four parts.
- Validation of scales/instrument for Swedish.
- Long-term results after reconstruction with latissimus dorsi- a ten year retrospective follow-up.
- Thoracodorsal artery perforator flap (TDAP) vs latissimus dorsi flap- a randomized controlled trial - breast reconstruction.
- TDAP vs Limber flap - a randomized controlled trial- reconstruction of axillary hidradenitis suppurativa.
Study Overview
Status
Recruiting
Conditions
Study Type
Interventional
Enrollment (Estimated)
550
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Emma Hansson, PhD, MD
- Phone Number: +46313421000
- Email: emma.hansson.2@gu.se
Study Locations
-
-
-
Gothenburg, Sweden, 413 45
- Recruiting
- Sahlgrenska University Hospital
-
Contact:
- Emma Hansson, PhD
- Phone Number: +46 31 342 10 00
- Email: emma.hansson.2@gu.se
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion criteria:
- Patients eligible for breast reconstruction following mastectomy and radiation
- Non-smokers or ex-smokers (>6 weeks)
- BMI < 30
Exclusion Criteria:
- Inability to leave informed consent
- Inability to understand Swedish
- Previous surgery with scaring on back
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Breast reconstruction TDAP
Breast reconstruction performed with TDAP
|
Breast reconstruction
Other Names:
|
Active Comparator: Breast reconstruction latissimus dorsi
Breast reconstruction performed with latissimus dorsi
|
Breast reconstruction
Other Names:
|
Active Comparator: Breast reconstruction with DIEP
Breast reconstruction performed with a deep inferior epigastric artery perforator flap
|
Breast reconstruction
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient satisfaction and breast-related quality of life after breast reconstruction
Time Frame: 10 years
|
Breast Q reconstruction.The BREAST-Q has multiple domains, each scored from 0 to 100 (higher scores indicate greater satisfaction or quality of life), there is no overall BREAST-Q score.
|
10 years
|
Back and shoulder function after breast reconstruction
Time Frame: 10 years
|
Breast Q the back and shoulder function scale.
The scale is scored from 0 (worst) to 100 (best).
Higher scores reflect a better outcome.
|
10 years
|
Back appearance after breast reconstruction
Time Frame: 10 years
|
Breast-Q the back appearance scale.The scale is scored from 0 (worst) to 100 (best).
Higher scores reflect a better outcome.
|
10 years
|
Shoulder function after breast reconstruction
Time Frame: 10 years
|
Western Ontario Osteoarthritis of the shoulder index (WOOS) provides scores on four domains: (1) physical symptoms; (2) sport, recreation, and work; (3) lifestyle; and (4) emotions.Each question has a possible score from 0-100 giving a total score up to 1900.
The highest or most symptomatic score is 1900 and the best or asymptomatic score is 0.
|
10 years
|
Abdominal satisfaction after breast reconstruction
Time Frame: 10 years
|
Breast Q abdominal satisfaction and abdominal well-being.The scale is scored from 0 (worst) to 100
|
10 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complications after breast reconstruction
Time Frame: 2 years
|
Measured in patients randomized to TDAP or latissimus dorsi flap.
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validation of Breast Q: The Back Appearance scale for Swedish
Time Frame: 1 year
|
Translation and validation of the instrument for Swedish
|
1 year
|
Validation of Breast-Q: The back and shoulder function scale for Swedish
Time Frame: 1 year
|
Translation and validation of the instrument for Swedish
|
1 year
|
Normal material for Breast-Q
Time Frame: 5 years
|
Measurement of quality of life according to breast-Q in a normative population
|
5 years
|
Normal material for Breast-Q back appearance scale
Time Frame: 5 years
|
Measurement of quality of life according to breast-Q back appaearance scale in a normative population
|
5 years
|
Normal material for Breast-Q back and shoulder function scale
Time Frame: 5 years
|
Measurement of quality of life according to breast-Q back and shoulder function scale in a normative population
|
5 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Estimated)
December 31, 2025
Study Completion (Estimated)
December 31, 2025
Study Registration Dates
First Submitted
August 12, 2020
First Submitted That Met QC Criteria
August 24, 2020
First Posted (Actual)
August 26, 2020
Study Record Updates
Last Update Posted (Actual)
August 8, 2023
Last Update Submitted That Met QC Criteria
August 7, 2023
Last Verified
August 1, 2023
More Information
Terms related to this study
Other Study ID Numbers
- 254-18
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on Thoracodorsal artery perforator flap to breast
-
Assiut UniversityUnknown
-
The National Institute of LymphologyThe DrMarga Practice Group; The Center for Restorative Breast Surgery, LLCUnknownBreast Cancer | Hereditary Breast/Ovarian Cancer (brca1, brca2) | Congenital Lymphedema | Acquired LymphedemaUnited States
-
Sohag UniversityRecruitingFailed Carpal Tunnel Syndrome SurgeryEgypt
-
Instituto do Cancer do Estado de São PauloRecruiting
-
I.M. Sechenov First Moscow State Medical UniversityRecruitingBreast Cancer | Postsurgical Acquired Absence of OrganRussian Federation